Stem cell therapy for Alzheimer's disease and related disorders: Current status and future perspectives

Experimental and Molecular Medicine

Volumn 47, Issue 3, 2015, Pages

  Tong, Leslie M ^a   Fong, Helen ^a,b   Huang, Yadong ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4;

ALZHEIMER DISEASE; AMYLOID PLAQUE; CELL DIFFERENTIATION; CELL LOSS; CELL PROLIFERATION; CELL TRANSFORMATION; CENTRAL NERVOUS SYSTEM; GABAERGIC SYSTEM; GENETIC ANALYSIS; GLIA CELL; HUMAN; HUMAN EMBRYONIC STEM CELL; IMMUNOSUPPRESSIVE TREATMENT; LEARNING DISORDER; MEMORY DISORDER; NERVE CELL; NEURAL STEM CELL TRANSPLANTATION; NEURONAL REPLACEMENT THERAPY; NONHUMAN; ONSET AGE; PATHOGENESIS; PLURIPOTENT STEM CELL; REVIEW; STEM CELL TRANSPLANTATION; ANIMAL; BIOLOGICAL THERAPY; DISEASE MODEL; RESEARCH;

ALZHEIMER DISEASE; ANIMALS; CELL- AND TISSUE-BASED THERAPY; DISEASE MODELS, ANIMAL; HUMANS; RESEARCH; STEM CELL TRANSPLANTATION;

EID: 84989323079     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2014.124     Document Type: Review

References (125)

1. Wimo A, Prince M. World Alzheimer Report 2010. The Global Economic Impact of Dementia. London, England, 2010.
2. Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012; 148: 1204-1222.
3. Golde TE, Schneider LS, Koo EH. Anti-Aβ therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron 2011; 69: 203-213.
4. Yu DX, Marchetto MC, Gage FH. Therapeutic translation of iPSCs for treating neurological disease. Cell Stem Cell 2013; 12: 678-688.
5. Mahley RW, Apolipoprotein E. Cholesterol transport protein with expanding role in cell biology. Science 1988; 240: 622-630.
6. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeus R et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. J Am Med Assoc 1997; 278: 1349-1356.
7. Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron 2010; 68: 270-281.
8. Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 2011; 16: 903-907.
9. Prasher VP, Farrer MJ, Kessling AM, Fisher EMC, West RJ, Barber PC et al. Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann Neurol 1998; 43: 380-383.
10. Ashe KH, Zahs KR. Probing the biology of Alzheimer's disease in mice. Neuron 2010; 66: 631-645.
11. Palop JJ, Mucke L. Amyloid-β-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci 2010; 13: 812-818.
12. Marchetti C, Marie H. Hippocampal synaptic plasticity in Alzheimer's disease: What have we learned so far from transgenic models? Rev Neurosci 2011; 22: 373-402.
13. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010; 362: 329-344.
14. Mucke L, Selkoe DJ. Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. In: Selkoe DJ, Mandelkow E, Holtzman DM (eds). The Biology of Alzheimer Disease. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, USA, 2011, pp 317-333.
15. Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ. Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci 2011; 31: 6627-6638.
16. Huang Y. Apolipoprotein E and Alzheimer disease. Neurology 2006; 66 (Suppl. 1): S79-S85.
17. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009; 63: 287-303.
18. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2000; 97: 2892-2897.
19. Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J et al. Apolipoprotein E is essential for amyloid deposition in the APPV717F transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 1999; 96: 15233-15238.
20. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides. Nat Med 2004; 10: 719-726.
21. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med 2011; 3: 89ra57.
22. Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003; 60: 1495-1500.
23. Berlau DJ, Corrada MM, Head E, Kawas CH. APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology 2009; 72: 829-834.
24. Squire LR, Wixted JT. The cognitive neuroscience of human memory since H.M. Annu Rev Neurosci 2011; 34: 259-288.
25. Wang SH, Morris RGM. Hippocampal-neocortical interactions in memory formation, consolidation, and reconsolidation. Annu Rev Psychol 2010; 61: 49-79.
26. Jasinska M, Siucinska E, Cybulska-Klosowicz A, Pyza E, Furness DN, Kossut M et al. Rapid, learning-induced inhibitory synaptogenesis in murin barrel field. J Neurosci 2010; 30: 1176-1184.
27. Brosh I, Barkai E. Learning-induced enhancement of feedback inhibitory synaptic transmission. Learn Mem 2009; 16: 413-416.
28. Nitz D, McNaughton B. Differential modulation of CA1 and dentate gyrus interneurons during exploration of novel environments. J Neurophysiol 2004; 91: 863-872.
29. Cui Y, Costa RM, Murphy GG, Elgersma Y, Zhu Y, Gutmann DH et al. Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell 2008; 135: 549-560.
30. Morellini F, Sivukhina E, Stoenica L, Oullanova E, Bukalo O, Jakovcevski I et al. Improved reversal learning and working memory and enhanced reactivity to novelty in mice with enhanced GABAergic innervation in the dentate gyrus. Cereb Cortex 2010; 20: 2712-2727.
31. Shi J, Cai Y, Liu G, Gong N, Liu Z, Xu T et al. Enhanced learning and memory in GAT1 heterozygous mice. Acta Biochem Biophys Sin 2012; 44: 359-366.
32. Hu JH, Ma YH, Jiang J, Yang N, Duan SH, Jiang ZH et al. Cognitive impairment in mice over-expressing gamma-aminobutyric acid transporter 1 (GAT1). Neuroreport 2004; 15: 9-12.
33. Andrews-Zwilling Y, Gillespie AK, Kravitz AV, Nelson AB, Devidze N, Lo I et al. Hilar GABAergic interneuron activity controls spatial learning and memory retrieval. PLoS ONE 2012; 7: e40555.
34. Verret L, Mann EO, Hang GB, Barth AM, Cobos I, Ho K et al. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 2012; 149: 708-721.
35. Meilandt WJ, Yu GQ, Chin J, Roberson ED, Palop JJ, Wu T et al. Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 2008; 28: 5007-5017.
36. Sanchez-Mejia RO, Newman JW, Toh S, Yu GQ, Zhou Y, Halabisky B et al. Phospholipase A2 reduction ameliorates cognitve deficits in mouse model of Alzheimer's disease. Nat Neurosci 2008; 11: 1311-1318.
37. Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichie ME et al. Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nat Neurosci 2011; 14: 750-756.
38. Andrews-Zwilling Y, Bien-Ly N, Xu Q, Li G, Bernardo A, Yoon SY et al. Apolipoprotein E4 causes age-and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. J Neurosci 2010; 30: 13707-13717.
39. Li G, Bien-Ly N, Andrews-Zwilling Y, Xu Q, Bernardo A, Ring K et al. GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice. Cell Stem Cell 2009; 5: 634-645.
40. Leung L, Andrews-Zwilling Y, Yoon SY, Ring K, Jain S, Walker D et al. Apolipoprotein E4 causes age-and sex-dependent impairments of hilar GABAergic interneurons and learning and memory deficits in mice. PLoS ONE 2012; 7: e53569.
41. Knoferle J, Yoon SY, Walker D, Leung L, Gillespie A, Tong L et al. Apolipoprotein E4 produced in GABAergic interneurons causes learning and memory deficits in mice. J Neurosci 2014; 34: 14069-14078.
42. Spiegel AM, Koh MT, Vogt NM, Rapp PR, Gallagher M. Hilar interneuron vulnerability distinguishes aged rats with memory impairment. J Comp Neurol 2013; 521: 3508-3523.
43. Koh MT, Spiegel AM, Gallagher M. Age-associated changes in hippocampal-dependent cognition in diversity outbred mice. Hippocampus 2014; 24: 1300-1307.
44. Bareggi SR, Franceschi M, Bonini L, Zecca L, Smirne S. Decreased CSF concentrations of homovanillic acid and γ-aminobutyric acid in Alzheimer's disease. Age-or disease-related modifications? Arch Neurol 1982; 39: 709-712.
45. Davies P, Katzman R, Terry RD. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementia. Nature 1980; 288: 279-280.
46. Hardy J, Cowburn R, Barton A, Reynolds G, Dodd P, O'Carroll AM et al. A disorder of cortical GABAergic innervation in Alzheimer's disease. Neurosci Lett 1987; 73: 192-196.
47. Seidl R, Cairns N, Singewald N, Kaehler ST, Lubec G. Differences between GABA levels in Alzheimer's disease and Down syndrome with Alzheimer-like neuropathology. Naunyn Schmiedeberg Arch Pharmacol 2001; 363: 139-145.
48. Zimmer R, Teelken AW, Trieling WB, Weber W, Weihmayr T, Lauter H. γ-Aminobutyric acid and homovanillic acid concentration in the CSF of patients with senile dementia of Alzheimer's type. Arch Neurol 1984; 41: 602-604.
49. Grouselle D, Winsky-Sommerer R, David JP, Delacourte A, Dournaud P, Epelbaum J. Loss of somatostatin-like immunoreactivity in the frontal cortex of Alzheimer patients carrying the apolipoprotein epsilon 4 allele. Neurosci Lett 1998; 255: 21-24.
50. Dennis NA, Browndyke JN, Stokes J, Need A, Burke JR, Welsh-Bohmer KA et al. Temporal lobe functional activity and connectivity in young adult APOE varepsilon4 carriers. Alzheimers Dement 2010; 6: 303-311.
51. Filippini N, MacIntosh BJ, Hough MG, Goodwin GM, Frisoni GB, Smith SM et al. Distinct patterns of brain activity in young carriers of the APOEepsilon4 allele. Proc Natl Acad Sci USA 2009; 106: 7209-7214.
52. Dickerson BC, Salat DH, Bales JF, Atiya M, Killany RJ, Greve DN et al. Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol 2004; 56: 27-35.
53. Dickerson BC, Salat DH, Greve DN, Chua EF, Rand-Giovannetti E, Rentz DM et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology 2005; 65: 404-411.
54. Celone KA, Calhoun VD, Dickerson BC, Atri A, Chua EF, Miller SL et al. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J Neurosci 2006; 26: 10222-10231.
55. Hämäläinen A, Pihaljamäki M, Tanila H, Hänninen T, Niskanen E, Tervo S et al. Increased fMRI responses during encoding in mild cognitive impairment. Neurobiol Aging 2007; 28: 1889-1903.
56. Yassa MA, Stark SM, Bakker A, Albert MS, Gallagher M, Stark CE. Highresolution structural and functional MRI of hippocampal CA3 and dentate gyrus in patients with amnestic mild cognitive impairment. Neuroimage 2010; 51: 1242-1252.
57. Tong LM, Djukic B, Arnold C, Gillespie AK, Yoon SY, Wang MM et al. Inhibitory interneuron progenitor transplantation restores normal learning and memory in apoE4 knock-in mice without or with Aβ accumulation. J Neurosci 2014; 34: 9506-9515.
58. Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE et al. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron 2012; 74: 467-474.
59. Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci USA 2012; 109: E2895-E2903.
60. Andressen C. Neural stem cells: from neurobiology to clinical applications. Curr Pharm Biotechnol 2013; 14: 20-28.
61. Choi SS, Lee SR, Kim SU, Lee HJ. Alzheimer's disease and stem cell therapy. Exp Neurobiol 2014; 23: 45-52.
62. Dunnett SB, Rosser AE. Challenges for taking primary and stem cells into clinical neurotransplantation trials for neurodegenerative disease. Neurobiol Dis 2014; 61: 79-89.
63. Chen WW, Blurton-Jones M. Concise review: can stem cells be used to treat or model Alzheimer's disease? Stem Cells 2012; 30: 2612-2618.
64. Chen C, Xiao SF. Induced pluripotent stem cells and neurodegenerative diseases. Neurosci Bull 2011; 27: 107-114.
65. Fan X, Sun D, Tang X, Cai Y, Yin ZQ, Xu H. Stem-cell challenges in the treatment of Alzheimer's disease: a long way from bench to bedside. Med Res Rev 2014; 34: 957-978.
66. Glat MJ, Offen D. Cell and gene therapy in Alzheimer's disease. Stem Cells Dev 2013; 22: 1490-1496.
67. Kim SU, de Vellis J. Stem cell-based cell therapy in neurological diseases: a review. J Neurosci Res 2009; 87: 2183-2200.
68. Li M, Guo K, Ikehara S. Stem cell treatment for Alzheimer's disease. Int J Mol Sci 2014; 15: 19226-19238.
69. Borlongan CV. Recent preclinical evidence advancing cell therapy for Alzheimer's disease. Expt Neurol 2012; 237: 142-146.
70. Kim SU, Lee HJ, Kim YB. Neural stem cell-based treatment for neurodegenerative diseases. Neuropathology 2013; 33: 491-504.
71. Liu AKL. Stem cell therapy for Alzheimer's disease: hype or hope? Biosci Horizons 2013; 6: hzt011.
72. Martínez-Morales PL, Revilla A, Ocana I, Gonzalez C, Sainz P, McGuire D et al. Progress in stem cell therapy for major human neurological disorders. Stem Cell Rev 2013; 9: 685-699.
73. Yuan SH, Martin J, Elia J, Flippin J, Paramban RI, Hefferan MP et al. Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells. PLoS ONE 2011; 6: e17540.
74. Hermann A, Storch A. Induced neural stem cells (iNSCs) in neurodegenerative diseases. J Neural Transm 2013; 120(Suppl): S19-S25.
75. Lee HJ, Kim KS, Kim EJ, Choi HB, Lee KH, Park IH et al. Brain transplantation of immortalized human neural stem cells promotes functional recovery in mouse intracerebral hemorrhage stroke model. Stem Cells 2007; 25: 1204-1212.
76. Yamasaki TR, Blurton-Jones M, Morrissette DA, Kitazawa M, Oddo S, LaFerla FM. Neural stem cells improve memory in an inducible mouse model of neuronal loss. J Neurosci 2007; 27: 11925-11933.
77. Xuan AG, Luo M, Ji WD, Long DH. Effects of engrafted neural stem cells in Alzheimer's disease rats. Neurosci Lett 2009; 450: 167-171.
78. Xuan AG, Long DH, Gu HG, Yang DD, Hong LP, Leng SL. BDNF improves the effects of neural stem cells on the rat model of Alzheimer's disease with unilateral lesion of fimbria-fornix. Neurosci Lett 2008; 440: 331-335.
79. Blurton-Jones M, Kitazawa M, Martinez-Coria H, Castello NA, Muller FJ, Loring JF et al. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci USA 2009; 106: 13594-13599.
80. Kwak YD, Brannen CL, Qu T, Kim HM, Dong X, Soba P et al. Amyloid precursor protein regulates differentiation of human neural stem cells. Stem Cells Dev 2006; 15: 381-389.
81. Wu S, Sasaki A, Yoshimoto R, Kawahara Y, Manabe T, Kataoka K et al. Neural stem cells improve learning and memory in rats with Alzheimer's disease. Pathobiology 2008; 75: 186-194.
82. Chen SQ, Cai Q, Shen YY, Wang PJ, Teng GJ, Li MH et al. 1)H-MRS evaluation of therapeutic effect of neural stem cell transplantation on Alzheimer's disease in AβPP/PS1 double transgenic mice. J Alzheimers Dis 2012; 28: 71-80.
83. Anderson S, Mione M, Yun K, Rubenstein JL. Differential origins of neocortical projection and local circuit neurons: role of Dlx genes in neocortical interneuronogenesis. Cereb Cortex 1999; 9: 646-654.
84. Tricoire L, Pelkey KA, Erkkila BE, Jeffries BW, Yuan X, McBain CJ. A blueprint for the spatiotemporal origins of mouse hippocampal interneuron diversity. J Neurosci 2011; 31: 10948-10970.
85. Marín O, Rubenstein JL. A long, remarkable journey: tangential migration in the telencephalon. Nat Rev Neurosci 2001; 2: 780-790.
86. Marin O. Directional guidance of interneuron migration to the cerebral cortex relies on subcortical Slit1/2-independent repulsion and cortical attraction. Development 2003; 130: 1889-1901.
87. Southwell DG, Froemke RC, Alvarez-Buylla A, Stryker MP, Gandhi SP. Cortical plasticity induced by inhibitory neuron transplantation. Science 2010; 327: 1145-1148.
88. Daadi MM, Lee SH, Arac A, Grueter BA, Bhatnagar R, Maag AL et al. Functional engraftment of the medial ganglionic eminence cells in experimental stroke model. Cell Transplant 2009; 18: 815-826.
89. Valente MF, Romariz S, Calcagnotto ME, Ruit L, Mello LE, Frussa-Filho R et al. Postnatal transplantation of interneuronal precursor cells decreases anxiety-like behavior in adult mice. Cell Transplant 2013; 22: 1237-1247.
90. Perez SM, Lodge DJ. Hippocampal interneuron transplants reverse aberrant dopamine system function and behavior in a rodent model of schizophrenia. Mol Psychiatry 2013; 18: 1193-1198.
91. Gilani AI, Chohan MO, Inan M, Schobel SA, Chaudhury NH, Paskewitz S et al. Interneuron precursor transplants in adult hippocampus reverse psychosis-relevant features in a mouse model of hippocampal disinhibition. Proc Natl Acad Sci USA 2014; 111: 7450-7455.
92. Martínez-Cerdeño V, Noctor SC, Espinosa A, Ariza J, Parker P, Orasji S et al. Embryonic MGE precursor cells grafted into adult rat striatum integrate and ameliorate motor symptoms in 6-OHDA-lesioned rats. Cell Stem Cell 2010; 6: 238-250.
93. Baraban SC, Southwell DG, Estrada RC, Jones DL, Sebe JY, Alfaro-Cervello C et al. Reduction of seizures by transplantation of cortical GABAergic interneuron precursors into Kv1.1 mutant mice. Proc Natl Acad Sci USA 2009; 106: 15472-15477.
94. Waldau B, Hattiangady B, Kuruba R, Shetty AK. Medial ganglionic eminence-derived neural stem cell grafts ease spontaneous seizures and restore GDNF expression in a rat model of chronic temporal lobe epilepsy. Stem Cells 2010; 28: 1153-1164.
95. Zipancic I, Calcagnotto ME, Piquer-Gil M, Mello LE, Alvarez-Dolado M. Transplant of GABAergic precursors restores hippocampal inhibitory function in a mouse model of seizure susceptibility. Cell Transplant 2010; 19: 549-564.
96. Hunt RF, Girskis KM, Rubenstein JL, Alvarez-Buylla A, Baraban SC. GABA progenitors grafted into the adult epileptic brain control seizures and abnormal behavior. Nat Neurosci 2013; 16: 692-697.
97. Tyson JA, Anderson SA. GABAergic interneuron transplants to study development and treat disease. Trends Neurosci 2014; 37: 169-177.
98. Calcagnotto ME, Zipancic I, Piquer-Gil M, Mello LE, Alvarez-Dolado M. Grafting of GABAergic precursors rescues deficits in hippocampal inhibition. Epilepsia 2010; 51(Suppl 3): 66-70 (2010).
99. Morgan RJ, Santhakumar V, Soltesz I. Modeling the dentate gyrus. Prog Brain Res 2007; 163: 639-658.
100. Amaral DG, Scharfman HE, Lavenex P. The dentate gyrus: fundamental neuroanatomical organization (dentate gyrus for dummies). Prog Brain Res 2007; 163: 3-22.
101. Watanabe K, Kamiya D, Nishiyama A, Katayama T, Nozaki S, Kawasaki H et al. Directed differentiation of telencephalic precursors from embryonic stem cells. Nat Neurosci 2005; 8: 288-296.
102. Maroof AM, Brown K, Shi SH, Studer L, Anderson SA. Prospective isolation of cortical interneuron precursors from mouse embryonic stem cells. J Neurosci 2010; 30: 4667-4675.
103. Petros TJ, Maurer CW, Anderson SA. Enhanced derivation of mouse ESCderived cortical interneurons by expression of Nkx2.1. Stem Cell Res 2013; 11: 647-656.
104. Maisano X, Litvina E, Tagliatela S, Aaron GB, Grabel LB, Naegele JR. Differentiation and functional incorporation of embryonic stem cellderived GABAergic interneurons in the dentate gyrus of mice with temporal lobe epilepsy. J Neurosci 2012; 32: 46-61.
105. Goulburn AL, Stanley EG, Elefanty AG, Anderson SA. Generating GABAergic cerebral cortical interneurons from mouse and human embryonic stem cells. Stem Cell Res 2012; 8: 416-426.
106. Liu Y, Weick JP, Liu H, Krencik R, Zhang X, Ma L et al. Medial ganglionic eminence-like cells derived from human embryonic stem cells correct learning and memory deficits. Nat Biotechnol 2013; 31: 1-10.
107. Nicholas CR, Chen J, Tang Y, Southwell DG, Chalmers N, Vogt D et al. Functional maturation of hPSC-derived forebrain interneurons requires an extended timeline and mimics human neural development. Cell Stem Cell 2013; 12: 573-586.
108. Maroof AM, Keros S, Tyson JA, Ying SW, Ganat YM, Merkle FT et al. Directed differentiation and functional maturation of cortical interneurons from human embryonic stem cells. Cell Stem Cell 2013; 12: 559-572.
109. Kim TG, Yao R, Monnell T, Cho JH, Vasudevan A, Koh A et al. Efficient specification of interneurons from human pluripotent stem cells by dorsoventral and rostrocaudal modulation. Stem Cells 2014; 32: 1789-1804.
110. Marín O. Human cortical interneurons take their time. Cell Stem Cell 2013; 12: 497-499.
111. Lujan E, Chanda S, Ahlenius H, Südhof TC, Wernig M. Direct conversion of mouse fibroblasts to self-renewing, tripotent neural precursor cells. Proc Natl Acad Sci USA 2012; 109: 2527-2532.
112. Han DW, Tapia N, Hermann A, Hemmer K, Hoing S, Arauzo-Bravo MJ et al. Direct reprogramming of fibroblasts into neural stem cells by defined factors. Cell Stem Cell 2012; 10: 465-472.
113. Thier M, Worsdorfer P, Lakes YB, Gorris R, Herms S, Opitz T et al. Direct conversion of fibroblasts into stably expandable neural stem cells. Cell Stem Cell 2012; 10: 473-479.
114. Ring KL, Tong LM, Balestra ME, Javier R, Andrews-Zwiling Y, Li G et al. Direct reprogramming of mouse and human fibroblasts into multipotent neural stem cells with a single factor. Cell Stem Cell 2012; 11: 100-109.
115. Zhou Q, Tripathi P. How to remake a fibroblast into a neural stem cell. Cell Stem Cell 2012; 10: 347-348.
116. Kim SM, Flaßkamp H, Hermann A, Arauzo-Bravo MJ, Lee SC, Lee SH et al. Direct conversion of mouse fibroblasts into induced neural stem cells. Nat Protoc 2014; 9: 871-881.
117. Corti S, Nizzardo M, Simone C, Falcone M, Donadoni C, Salani S et al. Direct reprogramming of human astrocytes into neural stem cells and neurons. Exp Cell Res 2012; 318: 1528-1541.
118. Sheng C, Zheng Q, Wu J, Xu Z, Wang L, Li W et al. Direct reprogramming of Sertoli cells into multipotent neural stem cells by defined factors. Cell Res 2012; 22: 208-218.
119. Hemmer K, Zhang M, van Wullen T, Sakalem M, Tapia N, Baumuratov A et al. Induced neural stem cells achieve long-term survival and functional integration in the adult mouse brain. Stem Cell Rep 2014; 3: 423-431.
120. Hitoshi S, Tropepe V, Ekker M, van der Kooy D. Neural stem cell lineages are regionally specified, but not committed, within distinct compartments of the developing brain. Development 2002; 244: 233-244.
121. Okano H, Temple S. Cell types to order: temporal specification of CNS stem cells. Curr Opin Neurobiol 2009; 19: 112-119.
122. Bock C, Kiskinis E, Verstappen G, Gu H, Boulting G, Smith ZD et al. Reference maps of human ES and iPS cell variation enable highthroughput characterization of pluripotent cell lines. Cell 2011; 144: 439-452.
123. Boulting GL, Kiskinis E, Croft GF, Amoroso MW, Oakley DH, Wainger BJ et al. A functionally characterized test set of human induced pluripotent stem cells. Nat Biotechnol 2011; 29: 279-286.
124. Mendez I, Sanchez-Pernaute R, Cooper O, Vinuela A, Ferrari D, Bjorklund L et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 2005; 128: 1498-1510.
125. Hallett PJ, Cooper O, Sadi D, Robertson H, Mendez I, Isacson O. Longterm health of dopaminergic neuron transplants in Parkinson's disease patients. Cell Rep 2014; 7: 1755-1761.